TULSA, Okla. (PRWEB)
June 03, 2022

Aberdeen Memory Care of Tulsa, a Sagora Senior Living community, has been awarded a zero-deficiency score on its annual state survey conducted by the Oklahoma Department of Health.

A zero-deficiency score is the highest grade that can be awarded to a community. It indicates that the community was in complete compliance with the state regulations that govern residential care, residential services, and the overall community environment.

The rigorous review process involves a community inspection, observation of daily activities, associate interviews, and an evaluation of community records. On average, these reviews find 7.5 deficiencies per Oklahoma assisted living community, meaning Aberdeen Memory Care of Tulsa is in elite company.

Aberdeen Memory Care of Tulsa offers specialized care for those with Alzheimer’s and dementia. Individualized, adaptive care focuses on providing residents with a sense of peace, comfort, and dignity while allowing them to remain active for as long as possible. Special programs include Dining With G.R.A.C.E., and the Cherished Memories Collection, which aim to promote stimulation, recognition and relaxation.

Share article on social media or email:

MADISON, Wis. (PRWEB)
June 03, 2022

EnsoData, the leading AI health care company helping clinicians uncover disease while patients sleep, today announces the closing of a $20 million Series A extension led by Inspire Medical Systems, Inc. (NYSE: INSP) (“Inspire”), with participation from existing investors including Zetta Venture Partners, Venture Investors, Supermoon Capital, Colle Capital, HealthX Ventures, M25 Ventures, Board members Justin Mortara, ​​Fred Robertson, MD, and other investors. The company is also expanding its leadership team with the appointment of Justin Mortara, PhD, as President. Coupled with funding and new partnerships, EnsoData’s latest additions to its senior leadership team will be essential as the company quickly scales to accelerate the adoption of AI technology across healthcare.

This news comes on the heels of EnsoData winning Inc. Magazine’s Best Workplaces award for the second year in a row.

One of the most widely used and adopted AI technologies clinically used today, EnsoData has experienced tremendous growth over the past year, driven by demand from customers seeking to enable faster and more accurate diagnoses and improve patient outcomes in the communities they serve. EnsoData is unlocking the role of sleep in human health and disease through the implementation of its novel AI solution and is laying the groundwork for a future in which some of healthcare’s most intractable problems – access and affordability for patients and clinician burnout – can be addressed through AI.

With its AI solution helping to diagnose patients with obstructive sleep apnea – a disease that goes undiagnosed in 80-90 percent of the population – EnsoData’s proven technology lays the foundation for expanding access and reach across health systems and clinics, payors and employers, and medical device and therapy companies in order to help improve health outcomes. Through partnerships with more than 100 leading provider organizations’ 500+ clinics across the U.S., over 500,000 patients have already benefited from EnsoData’s technology, and the company is helping 32,000+ new patients each month.

In the past year, EnsoData received its second FDA clearance, doubled its team in size, expanded partnerships with leading providers worldwide, and extended further support for virtual and at-home diagnostics. EnsoData’s world-class team has been recognized repeatedly for its culture of innovation, with its founding team being featured on Forbes 30 Under 30 in Healthcare list, and winning both the 2021 Wisconsin Inno Fire Award for health technology and the 2021 Wisconsin Innovation Award for Health IT.

With this new funding, EnsoData will rapidly scale multinational expansion and commercial distribution partnerships, continue building out its world-class team, and expand its product offerings to address new customer use cases and features to enable more accurate, affordable, and accessible care globally.

EnsoData is among the leading healthcare startups at the forefront of the digital shift in healthcare. The healthcare industry as a whole is at a major inflection point as trends like the overnight shift to telehealth in response to COVID-19 pandemic and the broad consumerization of healthcare have forced the industry to rapidly adopt novel technologies to catch up with the digital-first world. With a focus on increasing access and overall quality of care, EnsoData is uniquely positioned to help redefine the way service providers and health care systems address the multidimensional challenges facing the industry today – including a shrinking workforce, rising care costs, and poor compliance. EnsoData’s new partnership with Inspire represents a natural collaboration between two of the fastest-growing companies in the sleep and healthcare industry and will serve to help patients navigate their treatment journeys.

As President, Mortara will support EnsoData’s vision by preparing the company for scale in its next stage of growth – expanding EnsoData’s team, advancing its commercial strategy, and identifying new strategic opportunities. He brings 20 years of experience as a proven executive leader, innovator, and investor across digital health and life sciences. Previously he spent over 20 years at Mortara Instrument, a leading provider of diagnostics for cardiovascular disease, where as CEO he led the company to over 10x growth and market leadership, culminating in its acquisition in 2017 by Hillrom (Baxter) for $330m. Prior to joining in this role, Justin was EnsoData’s Executive Chairman and also managed a portfolio of early-stage healthcare investments spanning devices, tech-enabled services and life sciences.

Launched in 2015, EnsoData is among the earliest and largest in scale of real-world adoption and clinical use of AI across medicine today. With the first two FDA clearances on AI for Sleep, it represents one of the fastest, most accurate, and most interoperable AI technologies available to analyze and help diagnose diseases from data collected while people sleep. EnsoData’s proven technology is trained on the world’s largest sleep database, including more than 1,000,000 patient sleep studies and over 7,000,000 hours of resulting health waveform data.

Executive Quotes

— Chris Fernandez, CEO and Co-Founder of EnsoData, said: “EnsoData and its impactful technology represent an opportunity to improve the experience of treatment for patients and providers and accelerate big-picture shifts by opening greater access to diagnosis. Our proven, clinically validated technology has generated real demand and traction and as we continue to scale our team and growth. With this confluence of new funding, new partnerships, and the addition of industry veterans like Justin to our team, we’re even better positioned today to continue our upward trajectory and to successfully navigate the evolving state of healthcare.”

— Justin Mortara, President of EnsoData, said: “I’ve had the great pleasure to advise Chris and the EnsoData team for the last two years. During that time I have come to appreciate their culture, passion, and tremendous innovations in sleep. Drawing on my experience in cardiology, I see enormous potential for further growth and I am excited to start this next chapter as President.”

About EnsoData

EnsoData is a Waveform AI healthcare technology company that performs complex and time-consuming data interpretation and analysis. Our FDA cleared, AI-assisted sleep scoring solution, EnsoSleep, automates the scoring of studies, and reduces the time sleep clinicians otherwise spend working through hours of sleep data . This time savings provides clinicians with opportunities to expand patient care, improve outcomes and treat more patients. EnsoSleep’s additional products include EnsoViewer, an FDA cleared, web-based, interoperable sleep study reviewing, editing, and reporting software, and EnsoTST, which enables measurement of Total Sleep Time through more commonly available data found in home sleep apnea tests (HSATs).

For more information, visit https://www.ensodata.com/.

About Inspire Medical Systems

Inspire is a medical technology company focused on the development and commercialization of innovative and minimally invasive solutions for patients with obstructive sleep apnea. Inspire’s proprietary Inspire therapy is the first and only FDA-approved neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea.

For additional information about Inspire, please visit http://www.inspiresleep.com.

Press Contact:

Tess Pawlisch

ensodata (at) thekeypr (dot) com

FOOTHILL RANCH, Calif. (PRWEB)
June 03, 2022

Lighthouse Health & Wellness announces plans to assemble a Content Advisory Board. The board will serve to ensure the organization’s library of wellness content continues to be a relevant, high quality, and comprehensive resource for first responders and their families.

The Board Will Review & Advise

The Lighthouse Health & Wellness (LHHW) Content Advisory Board will be composed of subject matter experts and experienced public safety advocates across the nation. Members of the LHHW Content Advisory Board will be responsible for reviewing content for relevance, accuracy, and other quality assurance criteria, as well as making recommendations for content expansion and continued growth of the organization’s resources and information.

Developing More Targeted, Relevant Content

One such area of forecasted growth is increasing tailored resources for individual first responder vocations, such as firefighters, law enforcement officers, corrections officers, dispatch staff, and more. While all of these professionals are considered first responders, these roles require specialized skill sets and pose unique challenges to the individuals serving in the positions. Providing even more targeted resources that address and support these different specialties will take Lighthouse’s mission of putting quality content in the hands of first responders to the next level.

“Lighthouse’s content library is a core element of the collective resources we offer agencies, and it is critical that it continues to support first responders with the highest quality, most updated, and relevant information,” said Emily Marchetta, Director of Content and Partnerships at Lighthouse Health & Wellness. “Working with this panel will allow us to glean expertise and guidance from the most experienced voices in the industry. This will position Lighthouse to maintain the trust and confidence our agencies rely on us for, for years to come,” Marchetta said.

Made Possible by FirstNet®, Built with AT&T

The Lighthouse Health & Wellness Content Advisory Board is one of many new initiatives on the horizon for LHHW, as the organization’s recent collaboration with FirstNet®, Built with AT&T has provided additional resources and growth opportunities. FirstNet is built with AT&T in public-private partnership with the First Responder Network Authority, an independent agency within the federal government. It is the only nationwide, high-speed broadband communications platform dedicated to and purpose-built for America’s first responders and the extended public safety community.

AT&T’s founding sponsorship of Lighthouse strengthens and expands the impact of each organization’s mission. With AT&T’s support, Lighthouse Health & Wellness will be able to greatly accelerate wellness outreach efforts to first responders across the nation, expand its no-cost custom app development program, and continue to evolve the Lighthouse Health & Wellness Resource Library. This will further Lighthouse’s declared mission to foster the discovery, development and distribution of health and wellness tools and information that address the unique challenges faced by first responders and those who support them.

FirstNet and the FirstNet logo are registered trademarks of the First Responder Network Authority. All other marks are the property of their respective owners.

About Lighthouse Health & Wellness

Lighthouse Health & Wellness is a public benefit corporation with a mandated mission of ensuring that every public safety agency in the United States can provide its employees and their families with confidential and anonymous access to health and wellness resources. The organization accomplishes this by providing mobile app and web portal platforms that provide our nation’s first responders private access to culturally competent, cutting edge health and wellness information and resources. Beyond the technology platform, Lighthouse Health & Wellness also offers custom wellness programming and support plans that are specifically tailored to individual agency needs, and can include on-site support, coordinating speaking engagements, developing enrichment materials, peer support team training, and more. Lighthouse Health & Wellness was formed through parent company Apex Mobile’s work in creating mobile and app-based communications for law enforcement and public safety agencies throughout the US. For more information about the organization and their first responder health and wellness programs call 949-305-7008 or go to lighthousehw.org.

Share article on social media or email:

MILWAUKEE (PRWEB)
June 03, 2022

A survey of US oncology pharmacists recently published in JCO® Oncology Practice reports that oncology drug shortages continue to present serious barriers to providing effective cancer care. Disruptions caused by drug shortages can lead to delays in the timing of chemotherapy treatments, alterations in the dose or regimen administered, or even missed doses when alternative agents are unavailable. Read the JCO article.

“Persistent oncology drug shortages are a clear and growing challenge for healthcare organizations and those undergoing cancer treatment,” says Heidi D. Finnes, PharmD BCOP FHOPA, HOPA President and Senior Manager of Pharmacy Cancer Research at the Mayo Clinic Cancer Center. “Often, drug shortages stand in the way of providing optimal cancer care.”

The National Survey on the Effect of Oncology Drug Shortages in Clinical Practice: A Hematology Oncology Pharmacy Association (HOPA) Survey investigated the impact of oncology drug shortages in a variety of practice settings in the United States. Specifically, the survey examined the experiences of healthcare organizations, resource implications, impact on patient safety, and clinical trials.

The 36-item survey was distributed to HOPA members between December 2019 and July 2020 and 68 US organizations responded. Sixty-three percent of institutions reported one or more drug shortages per month, with a 34% increase in 2019 from 2018. Treatment delays, reduced doses, or alternative regimens were reported by 75% of respondents.

A drug shortage is defined as a period of time when the realized or projected demand for a drug exceeds the available supply. Prominent shortages include oncology medications and supportive care products that are essential to caring for people with cancer. In the HOPA survey, respondents said the most difficult agents to obtain were vincristine, vinblastine, intravenous immunoglobulin, leucovorin, and Bacillus Calmette Guerin (BCG).

Oncology drug shortages continue to be a threat to public health. While recent legislation related to COVID-19 relief, such as the CARES Act of 2020, has brought strategies to decrease drug shortages, additional action needs to occur.

“As advocates for the hematology/oncology pharmacy profession, as well as for those undergoing cancer treatment, HOPA members have a large stake in resolving these critical shortages,” says Dr. Finnes. A recent HOPA Drug Shortages Issue Brief provides recommendations for collaborative efforts among drug manufacturers, healthcare professionals, patient advocacy organizations, and government agencies to help mitigate disruptions caused by oncology drug shortages.

About HOPA: The Hematology/Oncology Pharmacy Association (HOPA) supports hematology/oncology pharmacy professionals and promotes the role of the pharmacist in collaborative cancer care. Founded in 2004, HOPA provides crucial education, networking, and advancement opportunities frequently sought by pharmacy interns, residents, fellows, students, technicians, researchers, and administrators who specialize in hematology/oncology pharmacy. Its vision is to ensure all individuals affected by cancer have a hematology/oncology pharmacist as an integral member of their care team.

Share article on social media or email: